Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open Ophth

Supplemental Figures and Tables

Supplemental Figure 1. Residual sum of squares (RSS) plot created for selection of the clinic-derived AT model.

k = 15

Supplement Figure 2 shows the 15 archetype model using the clinic optic neuritis visual fields. Note the patterns are similar to the 16 archetype model used for the study. Scale is -37 to 5 dB.

k = 17

Supplement Figure 3 shows the 15 archetype model using the clinic optic neuritis visual fields. Note the patterns are similar to the 16 archetype model used for the study. Scale is -37 to 5 dB

Clinic-derived AT	RW (%)	Avg. TD (dB)	ONTT-derived AT	RW (%)	Avg. TD (dB)
AT1	44.5	1.94	AT1	40.17	1.97
AT3	7.6	-33.10	AT2	9.35	-31.93
AT4	4.9	-21.91	AT7	4.16	-17.36
AT6	4.0	-23.53	AT12	2.34	-18.05
AT7	3.7	-19.46	AT11	2.57	-19.13
AT8	3.7	-6.72	AT5	5.17	-5.43
AT10	3.5	-11.19	AT4	5.29	-11.28
AT11	3.3	-10.42	AT10	3.06	-7.34
AT12	2.3	-13.11	AT15	2.08	-7.99
AT13	2.0	-17.67	AT14	2.22	-14.76
AT15	1.5	-23.11	AT13	2.32	-20.54

Supplemental Table 1: Relative weights (RWs) and average total deviation (TD) values for clinic-derived ATs and the Optic Neuritis Treatment Trial (ONTT)-derived ATs with similar patterns of loss.

	Clinic-derived	ONTT-derived	P-value
All severities	285.55	325.61	0.10
MD<-15 dB	1211.40	1366.33	0.62
-15≤MD<-7 dB	1070.69	1358.03	0.58
-7 ≤MD<-2 dB	265.29	269.15	0.47
MD≥-2 dB	116.65	141.48	0.29

Supplemental Table 2. Average SSE values for reconstruction of clinic VFs collected at final visits only using clinic-derived and Optic Neuritis Treatment Trial (ONTT)-derived models.

	Clinic-derived	ONTT-derived	P-value
All severities	552.12	642.44	<0.001
MD<-15 dB	1284.96	1562.34	<0.001
-15≤MD<-7 dB	1056.89	1252.78	0.02
-7 ≤MD<-2 dB	321.30	322.28	0.94
MD≥-2 dB	126.19	150.09	0.11

Supplemental Table 3. Average SSE values for reconstruction of all clinic VFs using clinic-derived and Optic Neuritis Treatment Trial (ONTT)-derived models.